<html><head></head><body><h1>EPINEPHrine (Systemic)</h1><p class="drug-subtitle"><b>Class:</b> alpha- and beta-Adrenergic Agonists<br/>
<b>VA Class:</b> AU100<br/>
<b>CAS Number:</b> 51-43-4<br/>
<b>Brands:</b> Adrenaclick, Adrenalin, Auvi-Q, EpiPen</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li>
<li>FAQ</li></ul><h2>Introduction</h2><p>Epinephrine is an endogenous catecholamine that is the active principle of the adrenal medulla; epinephrine acts directly on both α- and β-adrenergic receptors.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for EPINEPHrine (Systemic)</h2><h3>Sensitivity Reactions</h3><p>Drug of choice in the emergency treatment of severe acute anaphylactic reactions, including anaphylactic shock.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;169&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Used to relieve anaphylactic symptoms (e.g., urticaria, pruritus, angioedema, hypotension, respiratory distress) caused by reactions to drugs, contrast media, insect stings, foods (e.g., milk, eggs, fish, shellfish, peanuts, tree nuts), latex, or other allergens; also used for idiopathic or exercise-induced anaphylaxis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer immediately by IM injection as soon as anaphylaxis is diagnosed or strongly suspected.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administration by IM injection preferred, mainly because of safety considerations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;198&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;199&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;201&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; However, IV administration may be necessary in extreme situations (e.g., anaphylactic shock, cardiac arrest, unresponsive or severely hypotensive patients who have failed to respond to multiple IM injections).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;198&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;199&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;201&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Close hemodynamic monitoring is recommended during IV administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Also used for its vasopressor effects in the treatment of anaphylactic shock and cardiac arrest associated with anaphylaxis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Manage cardiac arrest secondary to anaphylaxis with standard ACLS measures; consider alternative vasoactive drugs (e.g., vasopressin, norepinephrine) in patients who do not respond to epinephrine.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See ACLS and Cardiac Arrhythmias under Uses.) Consider other interventions (e.g., antihistamines, inhaled β<sub>2</sub>-adrenergic agents, IV corticosteroids) as clinically indicated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of paradoxical response to epinephrine in patients receiving β-adrenergic blocking agents; consider glucagon and/or ipratropium for treatment of anaphylaxis in these patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>ACLS and Cardiac Arrhythmias</h3><p>Used for its α-adrenergic effects to increase blood flow and facilitate return of spontaneous circulation (ROSC) during cardiac arrest.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;179&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;400&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;402&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Principal benefits of the drug result from increases in aortic diastolic blood pressure and in coronary and cerebral blood flow during resuscitation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;400&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>High-quality CPR and defibrillation are the only proven interventions to increase survival to hospital discharge in ACLS.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;400&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Other resuscitative efforts, including drug therapy, are considered secondary and should be performed without compromising the quality and timely delivery of chest compressions and defibrillation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;400&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Principal goal of pharmacologic therapy during cardiac arrest is to facilitate ROSC, and epinephrine is the drug of choice for this use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;400&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>ACLS guidelines state that administration of epinephrine may be reasonable in adults with VF or pulseless VT resistant to initial CPR attempts and at least one defibrillation shock; optimal timing of administration (particularly in relation to defibrillation) not known and may vary based on patient-specific factors and resuscitation conditions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;400&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In adults with asystole or pulseless electrical activity (PEA), epinephrine may be administered as soon as feasible after onset of cardiac arrest.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;400&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Also may be used in the postresuscitation period to optimize BP, cardiac output, and systemic perfusion after ROSC.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;402&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;404&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Used during the periarrest period for treatment of symptomatic bradycardia in adults; although not a first-line drug, may be considered in patients who are unresponsive to atropine or as a temporizing measure while awaiting availability of a pacemaker.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Also used in the emergency treatment of infants and children with bradycardia and cardiopulmonary compromise (with a palpable pulse) when bradycardia persists despite ventilation, oxygenation, and chest compressions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Drugs are rarely needed during resuscitation of neonates; because hypoxemia and inadequate lung inflation are common causes of bradycardia, establishing adequate ventilation is the most important corrective measure in these patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;213&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;214&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Also has been used in the treatment of syncope resulting from AV nodal block.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; However, permanent pacemaker implantation is the treatment of choice for third-degree and advanced second-degree AV nodal block (complete heart block).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;182&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Septic Shock</h3><p>Used for treatment of hypotension associated with septic shock, generally as a second-line agent.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;204&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;207&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;208&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;209&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;235&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;238&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>The Surviving Sepsis Campaign International Guidelines for Management of Sepsis and Septic Shock recommend norepinephrine as the first-line vasopressor of choice in adults with septic shock; if adequate BP not achieved, epinephrine may be added.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;204&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;208&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Vasopressor therapy is <i>not</i> a substitute for replacement of blood, plasma, fluids, and/or electrolytes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Correct blood volume depletion as fully as possible before administration of epinephrine.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Should <i>not</i> be used in cardiogenic shock (because it increases myocardial oxygen demand) or in hemorrhagic or traumatic shock.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;206&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;208&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Local Vasoconstriction</h3><p>May be added to solutions of some local anesthetics to decrease the rate of vascular absorption (to localize and prolong the duration of anesthesia and decrease the risk of systemic toxicity).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;215&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;216&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Has been applied topically to control superficial bleeding from arterioles or capillaries in the skin, mucous membranes, or other tissues.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Bleeding from larger vessels is not controllable by topical application.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Premature Labor</h3><p>Has been used to relax uterine musculature and inhibit uterine contractions in premature labor† (tocolysis); however, the cardiovascular and other adverse effects limit its usefulness.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Pregnancy under Cautions.) Other β-agonists (e.g., terbutaline) preferred.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;165&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;173&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Bronchospasm</h3><p>Has been used as an oral bronchodilator for symptomatic treatment of asthma.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;166&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;191&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;192&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;194&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;236&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; However, an epinephrine preparation for oral inhalation no longer commercially available in US.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;166&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;223&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;236&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>While orally inhaled epinephrine was once widely used in the treatment of asthma,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;191&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;194&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; the drug has been replaced by more selective and rapid-acting agents (e.g., inhaled β<sub>2</sub>-adrenergic agonists).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;160&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;192&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;202&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;203&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Also has been used IV for treatment of severe asthma exacerbations; however, no evidence that the drug improves outcomes compared with selective inhaled β<sub>2</sub>-adrenergic agonists.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Upper GI Hemorrhage</h3><p>Has been used as an endoscopic treatment modality (as a dilute solution injected into and around ulcer base) to produce tamponade and achieve hemostasis in patients with acute nonvariceal upper GI bleeding†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;229&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;230&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;231&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;232&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;233&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;234&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Should not be used as monotherapy; use in combination with additional treatment modality (e.g., clips, thermocoagulation).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;229&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;230&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;231&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;232&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;233&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;234&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">EPINEPHrine (Systemic) Dosage and Administration</h2><h3>Administration</h3><p><i>Effective May 1, 2016, USP changed its labeling standard for all single-entity preparations of epinephrine injection, USP to require that dosage strengths be expressed only in terms of strength per mL (e.g., mg/mL).</i>&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;227&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>Use of ratio expressions (e.g., 1:1000 or 1:10,000) no longer is acceptable.</i>&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;226&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;227&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>Labeling change was prompted by numerous reports of serious medication errors caused by confusion with different ratio expressions.</i>&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;226&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Usually administered parenterally (by IM, sub-Q, or IV injection or by continuous IV infusion).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;169&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Select appropriate concentration and route of administration carefully; serious adverse effects (e.g., cerebral hemorrhage) have occurred after concentrated solutions of epinephrine intended for IM administration were administered IV.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;199&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;201&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;221&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Generally administer IV only in extreme situations (e.g., septic or anaphylactic shock, cardiac arrest, or when patient is unresponsive to multiple IM injections).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;198&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;199&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;201&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;204&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Always use dilute solutions of epinephrine (e.g., 0.1 mg/mL) when administering IV.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;101&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Commercially available epinephrine solutions for IM or sub-Q injection are more concentrated (1 mg/mL) and should not be administered IV without dilution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Also has been administered by intraosseous (IO) injection or infusion† in the ACLS setting, generally when IV access not readily available; onset of action and systemic concentrations are comparable to those achieved with venous administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May be administered endotracheally if vascular access (IV or IO) cannot be established during cardiac arrest.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;175&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Also has been administered by intracardiac injection (into the left ventricular chamber) during cardiac arrest;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;161&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; however, this route of administration not recommended in current ACLS guidelines.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;400&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Solutions of epinephrine have been applied topically to the skin, mucous membranes, or other tissues for local hemostasis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Also has been administered by oral inhalation in the treatment of asthma; however, an oral inhalation preparation no longer commercially available in the US.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;166&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;223&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;236&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Injections containing 1 mg/mL may be administered IM or sub-Q; avoid IM injections in the buttock.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;169&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;219&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;221&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; When epinephrine is used for the treatment of anaphylaxis, inject into anterolateral aspect of thigh; injection into or near smaller muscles (i.e., deltoid muscle) not recommended because of possible differences in absorption.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;169&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;219&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;221&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; When administered sub-Q, absorption and subsequent achievement of peak plasma concentrations is slower and may be substantially delayed if shock is present.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Commercially available as a prefilled auto-injector for emergency treatment of allergic reactions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;219&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;221&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; When using the auto-injector, administer appropriate weight-based dose by IM or sub-Q injection into anterolateral aspect of thigh; may administer through clothing if necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;219&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;221&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not reuse auto-injectors.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;220&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;222&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Consult manufacturer's prescribing information for additional instructions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;219&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;220&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;221&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;222&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For <i>self-medication</i>, instruct patients and caregivers about proper administration techniques using the auto-injector provided by the manufacturer.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;219&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;221&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; First aid providers should be familiar with the auto-injector in order to assist patients experiencing an anaphylactic reaction, and they should be able to administer the auto-injector in the event that patient is unable to self-administer, provided that state law permits and valid prescription exists.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;217&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For solution and drug compatibility information, see Compatibility under Stability.</p><p>May administer by slow, direct IV injection or continuous IV infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Commercially available as a 0.1-mg/mL solution for IV administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Must further dilute the commercially available 1-mg/mL solution prior to IV administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;101&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;238&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Extreme caution recommended when epinephrine is administered by direct IV injection since risk of overdosage and adverse cardiovascular effects is substantially higher; administer slowly and with close hemodynamic monitoring.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;198&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>During cardiac resuscitation, may administer IV into a central or peripheral line.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; CPR should not be interrupted for placement of a central line.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; After administration through a peripheral line, flush with 20 mL of IV fluid and elevate extremity to ensure drug delivery into central compartment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>To minimize risk of necrosis, administer continuous IV infusions into a large vein.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Avoid catheter tie-in technique to avoid stasis and increased local concentrations of the drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>Take care to avoid extravasation because local necrosis may result.</i>&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Must dilute the commercially available 1-mg/mL solution prior to IV administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;101&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;238&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Various methods have been described for diluting epinephrine solutions for IV administration; consult manufacturers' information for specific instructions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;101&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;238&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer slowly (after appropriate dilution) by IV injection or continuous IV infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Recommended rates of infusion vary based on indicated use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;404&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; While low rates (e.g., &lt;0.3 mcg/kg per minute) generally produce predominantly β-adrenergic effects and higher rates (e.g., &gt;0.3 mcg/kg per minute) produce α-adrenergic vasoconstriction,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; there is substantial interindividual variability; titrate infusion rate based on clinical response.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;404&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Dosage under Dosage and Administration.)</p><p>Apply solutions topically as a spray or on cotton or gauze to the skin, mucous membranes, or other tissues.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p>Dosage of epinephrine salts is expressed in terms of epinephrine.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>0.01 mg/kg (0.01 mL/kg of a 1-mg/mL solution) (up to 0.3–0.5 mg per dose depending on patient weight); repeat every 5–15 minutes as needed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;169&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;218&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Some clinicians state that doses may be repeated at 20-minute to 4-hour intervals depending on severity of the condition and patient response.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;211&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For <i>self-administration</i> using a prefilled auto-injector, inject 0.15 or 0.3 mg, depending on body weight; 0.3 mg recommended for patients weighing ≥30 kg and 0.15 mg recommended for patients weighing 15–30 kg.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;219&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;221&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Use alternative injectable forms if dose &lt;0.15 mg considered more appropriate.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;219&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;221&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; For severe persistent anaphylaxis, repeat doses may be needed; if &gt;2 sequential doses are required, administer subsequent doses only under direct medical supervision.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;219&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;221&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If necessary, initial dose of 0.01 mg/kg (0.1 mL/kg of a 0.1-mg/mL solution) may be administered.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;101&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If repeat doses are required, initiate a continuous IV infusion at a rate of 0.1 mcg/kg per minute; increase gradually to 1.5 mcg/kg per minute to maintain BP.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;101&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Neonates: Usual IV dose is 0.01–0.03 mg/kg (0.1–0.3 mL/kg of a 0.1-mg/mL solution).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;213&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;214&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Higher doses not recommended because of risk of exaggerated hypertension, decreased myocardial function, and worsening neurologic function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;213&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Pediatric patients: Usual IV/IO dose is 0.01 mg/kg (0.1 mL/kg of a 0.1-mg/mL solution), up to a maximum single dose of 1 mg, repeated every 3–5 minutes as needed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;402&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Lack of survival benefit and potential harm from routine use of higher doses, particularly in cases of asphyxia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;181&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; However, may consider high-dose epinephrine in exceptional circumstances (e.g., β-adrenergic blocking agent overdose).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For postresuscitation stabilization in pediatric patients, usual dosage is 0.1–1 mcg/kg per minute by IV/IO infusion; adjust based on patient response.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Low-dose infusions (&lt;0.3 mcg/kg per minute) generally produce predominantly β-adrenergic effects, while higher-dose infusions (&gt;0.3 mcg/kg per minute) result in α-adrenergic vasoconstriction.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For emergency treatment of infants and children with bradycardia and cardiopulmonary compromise (with a palpable pulse), may give 0.01 mg/kg (0.1 mL/kg of a 0.1-mg/mL solution) by IV/IO injection, repeated every 3–5 minutes as needed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Optimum dose not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Neonates: If endotracheal route is used, doses of 0.01 or 0.03 mg/kg will likely be ineffective.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;213&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Although safety and efficacy not established, consider endotracheal administration of a higher dose (0.05–0.1 mg/kg) while IV access is being obtained.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;213&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;214&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Pediatric patients: Usual dose is 0.1 mg/kg (0.1 mL/kg of a 1-mg/mL solution), up to a maximum single dose of 2.5 mg, for cardiac resuscitation; repeat every 3–5 minutes as needed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;402&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Flush with at least 5 mL of 0.9% sodium chloride injection after each dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For emergency treatment of infants and children with bradycardia and cardiopulmonary compromise (with a palpable pulse), may administer endotracheally at a dose of 0.1 mg/kg (0.1 mL/kg of a 1-mg/mL solution) if IV/IO access not available.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If epinephrine is used in pediatric patients, some clinicians have recommended an infusion rate of 0.05–0.3 mcg/kg per minute, titrated to effect.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;204&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;237&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>When therapy is discontinued, decrease infusion rate gradually (e.g., by reducing every 30 minutes over a 12- to 24- hour period).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Pediatric patients ≤12 years of age: For severe asthma, inject 0.01 mg/kg (0.01 mL/kg of a 1-mg/mL solution) every 20 minutes as needed for 3 doses; do not exceed 0.3–0.5 mg per dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;160&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adolescents &gt;12 years of age: 0.3–0.5 mg every 20 minutes as needed for 3 consecutive doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;160&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;162&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Neonates: 0.01 mg/kg by slow IV injection has been recommended.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;211&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Infants: Initially, 0.05 mg by slow IV injection; may repeat every 20–30 minutes as needed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;211&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Usual dose is 0.2–0.5 mg (0.2–0.5 mL of a 1-mg/mL solution); repeat every 5–15 minutes as needed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;169&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For <i>self-administration</i> using a prefilled auto-injector, inject 0.3 mg.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;219&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;221&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; For severe persistent anaphylaxis, repeat doses may be needed; if &gt;2 sequential doses are needed, administer subsequent doses only under direct medical supervision.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;219&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;221&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In extreme circumstances (e.g., anaphylactic shock, cardiac arrest, or no response to initial IM injections), IV administration may be necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;175&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;198&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;201&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Usual IV dose is 0.1–0.25 mg (1–2.5 mL of a 0.1-mg/mL solution); repeat every 5–15 minutes as necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Alternatively, may administer as a continuous infusion at a rate of 2–15 mcg/minute; titrate based on severity of the reaction and clinical response.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>ACLS guidelines recommend 1 mg every 3–5 minutes by IV/IO injection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;400&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Higher doses (e.g., 0.1–0.2 mg/kg) do not provide any benefits in terms of survival or neurologic outcomes compared with the standard dose (1 mg) and may be harmful.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;115&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;118&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;175&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;400&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Optimal timing of administration, particularly in relation to defibrillation, not known and may vary based on patient-specific factors and resuscitation conditions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;400&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In adults with asystole or PEA, may administer as soon as feasible after onset of cardiac arrest based on studies demonstrating improved survival to hospital discharge and increased ROSC when the drug is administered early during course of treatment for a nonshockable rhythm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;400&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For postresuscitation stabilization, usual IV dosage is 0.1–0.5 mcg/kg per minute; adjust based on patient response.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;404&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Optimal dose not established, but typical doses are 2–2.5 times those administered IV.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For symptomatic bradycardia, initial IV infusion rate of 2–10 mcg/minute has been recommended; adjust according to patient response.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In conjunction with local anesthetics, has been used in concentrations of 0.002–0.02 mg/mL; most frequently used concentration is 0.005 mg/mL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>As a topical hemostatic, solution concentrations of 0.002–0.1% have been sprayed or applied with cotton or gauze to the skin, mucous membranes, or other tissues.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Manufacturer suggests IV infusion of 0.05–2 mcg/kg per minute.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; May increase infusion rate by 0.05–0.2 mcg/kg per minute every 10–15 minutes to achieve desired BP goal.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Duration of therapy or total dose required not known; treatment may be necessary for several hours or days until the patient's hemodynamic status improves.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>When therapy is discontinued, decrease infusion rate gradually (e.g., by reducing every 30 minutes over a 12- to 24-hour period).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For severe asthma, 0.3–0.5 mg (0.3–0.5 mL of a 1-mg/mL solution) may be administered every 20 minutes for 3 doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;160&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Alternatively, may administer 0.01 mg/kg (using a 1-mg/mL solution) divided into 3 doses of approximately 0.3 mg each, given at 20-minute intervals.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>0.1–0.25 mg (1–2.5 mL of a 0.1-mg/mL solution) injected slowly.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Prescribing Limits</h3><p>Maximum for pediatric patients: 0.3–0.5 mg of epinephrine per dose depending on weight.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;169&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;211&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;218&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Maximum single dose of 1 mg.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;402&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Maximum single dose of 2.5 mg.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Maximum for pediatric patients ≤12 years of age: 0.3–0.5 mg per dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;160&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;162&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Single doses should not exceed 0.5 mg.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;169&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for EPINEPHrine (Systemic)</h2><h3>Contraindications</h3><ul>
<li>
<p>No <i>absolute</i> contraindications to use in life-threatening conditions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Relative contraindications include shock (other than anaphylactic and septic shock), known hypersensitivity to sympathomimetic amines, coronary insufficiency, or cardiac dilatation, as well as use in most patients with angle-closure glaucoma, or organic brain damage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Contraindicated for use during general anesthesia with agents such as cyclopropane and halogenated hydrocarbon anesthetics (e.g., halothane).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Contraindicated in conjunction with local anesthetics for use in certain areas (e.g.,fingers, toes, ears).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>No <i>absolute</i> contraindications to use in life-threatening conditions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Relative contraindications include shock (other than anaphylactic and septic shock), known hypersensitivity to sympathomimetic amines, coronary insufficiency, or cardiac dilatation, as well as use in most patients with angle-closure glaucoma, or organic brain damage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Contraindicated for use during general anesthesia with agents such as cyclopropane and halogenated hydrocarbon anesthetics (e.g., halothane).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Contraindicated in conjunction with local anesthetics for use in certain areas (e.g.,fingers, toes, ears).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>Inadvertent induction of high arterial BP with epinephrine can cause angina pectoris, aortic rupture, or cerebral hemorrhage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Vasopressor therapy is <i>not</i> a substitute for replacement of blood, plasma, fluids, and/or electrolytes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Correct blood volume depletion as fully as possible before epinephrine administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Avoid extravasation; severe local adverse effects (e.g., tissue necrosis) may occur as a result of local vasoconstriction.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p><i>Check site of infusion frequently for free flow and observe infused vein for blanching.</i>&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Avoid injection into leg veins, especially in geriatric patients or those with occlusive vascular diseases (e.g., arteriosclerosis, atherosclerosis, Buerger’s disease, diabetic endarteritis).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If blanching is observed in the infused vein, changing the injection site periodically may be advisable.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If extravasation occurs, infiltrate affected area liberally with 10–15 mL of sodium chloride solution containing 5–10 mg of phentolamine mesylate.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Immediate and conspicuous local hyperemic changes occur if area is infiltrated within 12 hours; therefore, administer phentolamine as soon as possible after extravasation noted.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adverse reactions most likely to occur in hypertensive or hyperthyroid patients; use with extreme caution, if at all.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution in patients with Parkinson's disease, diabetes mellitus, pheochromocytoma, cardiovascular disease, or psychoneurotic disorders.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Can induce serious cardiac arrhythmias in patients without heart disease, in those with organic heart disease, and in those with drug-induced myocardial sensitization.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Can convert asystole to VF in anesthetic cardiac accidents since many anesthetics sensitize the myocardium to epinephrine.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Cyclopropane or halogenated hydrocarbon general anesthetics that increase cardiac irritability and seem to sensitize the myocardium to epinephrine may cause arrhythmias including VPC, VT, or VF.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Contraindications under Cautions.)</p><p>Some formulations contain sulfites, which may cause allergic-type reactions (including anaphylaxis and life-threatening or less severe asthmatic episodes) in certain susceptible individuals.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;102&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Presence of sulfites in a parenteral epinephrine preparation and the possibility of allergic-type reactions should <i>not</i> deter use of the drug when indicated for the treatment of serious allergic reactions or for other emergency situations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;102&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Epinephrine is the preferred treatment for such conditions, and currently available alternatives to epinephrine may not be optimally effective.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;102&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Consider that sulfites may be responsible for paradoxical worsening of respiratory function in asthmatics or for worsening symptoms or decreased bronchodilatory response with increasing use of the drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Caution in those with a history of sensitivity to sympathomimetic amines.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Can cause VF, but beneficial effects in restoring electrical activity and enhancing defibrillation are well documented.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May cause tachycardia, ventricular ectopy, tachyarrhythmias, hypertension, and vasoconstriction in patients with a perfusing rhythm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;175&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Caution in patients with underlying cardiovascular disease (e.g., cardiac arrhythmias, coronary artery disease, organic heart disease).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Extreme caution in patients with prefibrillatory rhythm because of excitatory cardiac activity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Overdosage or inadvertent IV administration may cause cerebrovascular hemorrhage secondary to a marked increase in BP.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Caution in patients with long-standing bronchial asthma and substantial emphysema who may also have degenerative heart disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Can cause pulmonary edema secondary to peripheral vasoconstriction and cardiac stimulation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May decrease vascular vasopressor response.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use vasopressors cautiously with MAO inhibitors.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Category C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use during pregnancy only if clearly indicated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Some manufacturers state that epinephrine injection should be avoided during the second stage of labor or when maternal BP is &gt;130/80 mm Hg.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>When administered in ACLS, may decrease blood flow to the uterus; however, the woman must be resuscitated for survival of the fetus.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk unknown.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;171&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Used in pediatric patients of all ages, dosing according to body weight.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;101&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;160&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;162&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Common Adverse Effects</h3><p>Fear, anxiety, tenseness, restlessness, headache, tremor, dizziness, lightheadedness, nervousness, sleeplessness, excitability, and weakness.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Increased rigidity and tremor in patients with parkinsonian syndrome. May aggravate or induce psychomotor agitation, disorientation, impaired memory, assaultive behavior, panic, hallucinations, suicidal or homicidal tendencies, and psychosis characterized by clear consciousness with schizophrenic-like thought disorder and paranoid delusions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Nausea, vomiting, sweating, pallor, respiratory difficulty, or respiratory weakness and apnea.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>ECG changes including a decrease in T-wave amplitude in all leads in normal individuals.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Disturbances of cardiac rhythm and rate may result in palpitation and tachycardia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Aggravation or precipitation of angina pectoris by increasing cardiac work and accentuating the insufficiency of the coronary circulation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Potentially fatal ventricular arrhythmias including fibrillation, especially in patients with organic heart disease or those receiving other drugs that sensitize the heart to arrhythmias.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Hypertension secondary to overdosage or inadvertent IV injection of usual sub-Q doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Subarachnoid hemorrhage and hemiplegia have resulted from hypertension, even following usual sub-Q doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Necrosis from repeated injections because of vascular constriction at the injection site.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Tissue necrosis in the extremities, kidneys, and liver.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Severe metabolic acidosis from prolonged use or overdosage because of elevated blood concentrations of lactic acid.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Absorption from the respiratory tract following large orally inhaled doses may result in adverse effects similar to those occurring after parenteral administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Rebound bronchospasm may occur when the effects of epinephrine end.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Further reductions in arterial oxygen tension.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Dryness of pharyngeal membranes may follow oral inhalation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for EPINEPHrine (Systemic)</h2><h3>Specific Drugs</h3><p>Drug</p><p>Interaction</p><p>Comments</p><p>α-Adrenergic blocking agents (e.g., phentolamine)</p><p>High-dose epinephrine vasoconstriction and hypertension antagonized&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>β-Adrenergic blocking agents (e.g., propranolol)</p><p>Antagonism of cardiac and bronchodilating effects&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May potentiate pressor effects of epinephrine&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Anesthetics, general (e.g., halogenated hydrocarbons [e.g., halothane], cyclopropane)</p><p>Increased cardiosensitivity to epinephrine&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution, if at all; increased risk of ventricular arrhythmias such as VPCs, VT, or VF; contraindicated with chloroform, trichloroethylene, or cyclopropane&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May not be absorbed rapidly enough with topical hemostatic use to present a problem in short procedures&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Prophylactic lidocaine or procainamide may provide some protection&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>IV propranolol may reverse arrhythmias&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Antidepressants, MAO inhibitors</p><p>MAO is one enzyme involved in epinephrine metabolism&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May cause severe, prolonged hypertension&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Antidepressants, tricyclic</p><p>Potentiation of epinephrine effects (especially on heart rate and rhythm)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Antidiabetic agents (e.g., insulin, oral hypoglycemics)</p><p>Epinephrine-induced hyperglycemia&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May require increased antidiabetic dosage&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Antihistamines, first generation (especially diphenhydramine, dexchlorpheniramine, tripelennamine)</p><p>Potentiation of epinephrine effects (especially on heart rate and rhythm)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Antihypertensives</p><p>Antagonism of pressor effects of epinephrine&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Catechol-<i>O</i>-methyltransferase (COMT) inhibitors (e.g., entacapone)</p><p>Potentiation of pressor effects of epinephrine&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Clonidine</p><p>Potentiation of pressor effects of epinephrine&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Corticosteroids</p><p>Potentiation of hypokalemic effects of epinephrine&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Digoxin</p><p>Increased cardiosensitivity to epinephrine&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Avoid epinephrine with excessive digoxin dosages&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Diuretics</p><p>Antagonism of pressor effects and potentiation of arrhythmogenic effects of epinephrine&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Some diuretics may potentiate the hypokalemic effects of epinephrine&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Doxapram</p><p>Potentiation of pressor effects of epinephrine&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Ergot alkaloids</p><p>α-Adrenergic antagonism&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible reversal of pressor response&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Nitrates</p><p>Antagonism of pressor effects of epinephrine&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Oxytocics</p><p>Severe, persistent, hypertension possible&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Phenothiazines</p><p>Reversal of epinephrine's vasopressor effect&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Do <i>not</i> use to treat phenothiazine-induced hypotension&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Quinidine</p><p>May potentiate arrhythmogenic effects of epinephrine&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Sympathomimetic amines</p><p>Additive effects and toxicity&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Avoid concomitant use&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Theophylline</p><p>Potentiation of hypokalemic effects of epinephrine&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Thyroid hormones</p><p>Potentiation of epinephrine effects (especially on heart rate and rhythm)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">EPINEPHrine (Systemic) Pharmacokinetics</h2><h3>Absorption</h3><p>Rapidly metabolized in the GI tract and liver after oral ingestion; pharmacologically active concentrations are not reached when given orally.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Well absorbed after sub-Q or IM injection; absorption can be hastened by massaging the injection site.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Absorbed rapidly through the lung capillary bed following endotracheal administration;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; serum concentrations achieved only 10% of those with an equivalent IV dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;161&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Absorption is slight and the effects are restricted mainly to the respiratory tract after usual orally inhaled doses; absorption somewhat increased when larger doses are inhaled, and systemic effects may occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Rapid onset of action when solutions are administered parenterally or by oral inhalation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Sub-Q injection in asthmatic attacks may produce bronchodilation within 5–10 minutes and maximal effects in about 20 minutes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>After oral inhalation, bronchodilation usually occurs within 1 minute.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Short duration of action when solutions are administered parenterally or by oral inhalation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Distribution</h3><p>Epinephrine crosses the placenta but not the blood-brain barrier.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Elimination</h3><p>Pharmacologic actions are terminated mainly by uptake and metabolism in sympathetic nerve endings.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Circulating drug is metabolized in the liver and other tissues by a combination of reactions involving the enzymes catechol-<i>O</i>-methyltransferase (COMT) and MAO.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>40% excreted in urine, mainly as inactive metabolites.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>Epinephrine, epinephrine salts, and preparations containing the drug gradually darken on exposure to light and air and must be stored in tight, light-resistant containers.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;167&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Discard solutions with a color that is pinkish or darker than slightly yellow or that contain a precipitate.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;167&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Commercially available preparations vary in stability, depending on the form in which epinephrine is present and on the preservatives used.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Follow the manufacturer’s directions with respect to storage requirements for each product.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Epinephrine: 20–25°C; protect from light and freezing.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;169&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;238&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In some commercially available injections, air has been replaced with nitrogen to avoid oxidation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Withdrawal of doses from multiple-dose vials introduces air into the vials, subjecting the remaining epinephrine to oxidation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Oxidation of epinephrine imparts first a pink, then a brown color.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Auto-injector (e.g., EpiPen<sup></sup>): 20–25°C (may be exposed to 15–30°C); protect from light and do not refrigerate or freeze.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Manufacturer's plastic carrying case provides added UV light protection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;220&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;222&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Avoid exposure to extreme heat or cold.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Compatibility</h3><p>For information on systemic interactions resulting from concomitant use, see Interactions.</p><p>Incompatible with sodium bicarbonate and other alkaline solutions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;175&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Compatibility studies conducted using epinephrine hydrochloride.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;HID&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Compatible</p><p>Dextrose–Ringer’s injection combinations</p><p>Dextrose–Ringer’s injection, lactated, combinations</p><p>Dextrose 5% in Ringer’s injection, lactated</p><p>Dextrose–saline combinations</p><p>Dextrose 5% in sodium chloride 0.9%</p><p>Dextrose 2.5, 5, or 10% in water</p><p>Ionosol products (except as noted below)</p><p>Ringer’s injection</p><p>Ringer’s injection, lactated</p><p>Sodium chloride 0.9%</p><p>Sodium lactate 1/6 M</p><p>Incompatible</p><p>Ionosol T in dextrose 5%</p><p>Sodium bicarbonate 5%</p><p>Compatibility studies conducted using epinephrine hydrochloride.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;HID&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Compatible</p><p>Amikacin sulfate</p><p>Bupivacaine HCl</p><p>Dobutamine HCl</p><p>Fentanyl citrate</p><p>Floxacillin sodium</p><p>Furosemide</p><p>Ranitidine HCl</p><p>Verapamil HCl</p><p>Incompatible</p><p>Aminophylline</p><p>Compatible</p><p>Amiodarone HCl</p><p>Anidulafungin</p><p>Atracurium besylate</p><p>Bivalirudin</p><p>Calcium chloride</p><p>Calcium gluconate</p><p>Caspofungin acetate</p><p>Ceftazidime</p><p>Cisatracurium besylate</p><p>Clonidine HCl</p><p>Dexmedetomidine HCl</p><p>Diltiazem HCl</p><p>Dobutamine HCl</p><p>Dopamine HCl</p><p>Famotidine</p><p>Fenoldopam mesylate</p><p>Fentanyl citrate</p><p>Furosemide</p><p>Heparin sodium</p><p>Hetastarch in lactated electrolyte injection (Hextend)</p><p>Hydrocortisone sodium succinate</p><p>Hydromorphone HCl</p><p>Labetalol HCl</p><p>Levofloxacin</p><p>Lorazepam</p><p>Midazolam HCl</p><p>Milrinone lactate</p><p>Morphine sulfate</p><p>Nicardipine HCl</p><p>Nitroglycerin</p><p>Norepinephrine bitartrate</p><p>Pancuronium bromide</p><p>Pantoprazole sodium</p><p>Phytonadione</p><p>Potassium chloride</p><p>Propofol</p><p>Ranitidine HCl</p><p>Remifentanil HCl</p><p>Sodium nitroprusside</p><p>Tigecycline</p><p>Tirofiban HCl</p><p>Vasopressin</p><p>Vecuronium bromide</p><p>Warfarin sodium</p><p>Incompatible</p><p>Ampicillin sodium</p><p>Hydroxyethyl starch 130/0.4 in sodium chloride 0.9%</p><p>Micafungin sodium</p><h2>Actions</h2><ul>
<li>
<p>An endogenous catecholamine.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Acts directly on both α- and β-adrenergic receptors of tissues innervated by sympathetic nerves except the sweat glands and arteries of the face.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Main effects of therapeutic parenteral doses are relaxation of smooth muscle of the bronchial tree, cardiac stimulation, and dilation of skeletal muscle vasculature.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Relaxes bronchial smooth muscle by stimulation of β<sub>2</sub>-adrenergic receptors and constricts bronchial arterioles by stimulation of α-adrenergic receptors.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Relieves bronchospasm, reduces congestion and edema, and increases tidal volume and vital capacity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Inhibits histamine release and antagonizes the effect of the mediator on end organs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; As a result, may reverse histamine-induced bronchiolar constriction, vasodilation, and edema.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Acts on β<sub>1</sub>-adrenergic receptors in the heart, producing a positive chronotropic effect through the SA node and a positive inotropic effect on the myocardium.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;175&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Cardiac output, oxygen consumption, and the work of the heart are increased.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Constricts arterioles in the skin, mucous membranes, and viscera by its effect on α-adrenergic receptors and reduces cutaneous blood flow, especially in the hands and feet.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Produces local vasoconstriction and hemostasis in bleeding from small vessels when applied topically but does not control bleeding from larger vessels.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>An endogenous catecholamine.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Acts directly on both α- and β-adrenergic receptors of tissues innervated by sympathetic nerves except the sweat glands and arteries of the face.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Main effects of therapeutic parenteral doses are relaxation of smooth muscle of the bronchial tree, cardiac stimulation, and dilation of skeletal muscle vasculature.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Relaxes bronchial smooth muscle by stimulation of β<sub>2</sub>-adrenergic receptors and constricts bronchial arterioles by stimulation of α-adrenergic receptors.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Relieves bronchospasm, reduces congestion and edema, and increases tidal volume and vital capacity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Inhibits histamine release and antagonizes the effect of the mediator on end organs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; As a result, may reverse histamine-induced bronchiolar constriction, vasodilation, and edema.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Acts on β<sub>1</sub>-adrenergic receptors in the heart, producing a positive chronotropic effect through the SA node and a positive inotropic effect on the myocardium.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;175&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Cardiac output, oxygen consumption, and the work of the heart are increased.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Constricts arterioles in the skin, mucous membranes, and viscera by its effect on α-adrenergic receptors and reduces cutaneous blood flow, especially in the hands and feet.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Produces local vasoconstriction and hemostasis in bleeding from small vessels when applied topically but does not control bleeding from larger vessels.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Importance of advising patients or their caregivers about common adverse effects with epinephrine including tachycardia, palpitations, sweating, nausea, vomiting, difficulty breathing, pallor, dizziness, weakness, shakiness, headache, apprehension, nervousness, or anxiety.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; These effects may be more persistent or severe in patients with hypertension or hyperthyroidism, and patients with coronary artery disease could experience angina.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of advising patients with diabetes mellitus that epinephrine may increase blood glucose and advising patients with Parkinson's disease that the drug may cause a temporary worsening of symptoms.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>For <i>self-administration</i> in anaphylaxis, instruct patients on proper techniques for storage, expiration dating (replacing before expiration), use, and disposal of prefilled auto-injectors (e.g., EpiPen<sup></sup>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;219&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;220&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;221&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;222&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of advising patients to go to the nearest emergency room after <i>self-administration</i> for anaphylaxis since further medical attention may be needed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Instruct patient to inform clinician that epinephrine was self-administered (show injection site) and to bring used auto-injector for proper disposal.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Give patients a copy of the manufacturer’s patient instructions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of not injecting the dose via the auto-injector into the thumb, finger, or hand since loss of blood flow may occur in these areas.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of seeking immediate medical attention if this occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>For anaphylaxis, importance of remaining vigilant for possible recurrence despite an asymptomatic period;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;161&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;175&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; length of observation time not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;175&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Symptoms may recur within 1–36 hours after initial reaction.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;175&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Some experts suggest that patients with moderate to severe anaphylaxis should be observed for a minimum of 4–8 hours after treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant diseases.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p>
</li>
</ul><p>Importance of advising patients or their caregivers about common adverse effects with epinephrine including tachycardia, palpitations, sweating, nausea, vomiting, difficulty breathing, pallor, dizziness, weakness, shakiness, headache, apprehension, nervousness, or anxiety.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; These effects may be more persistent or severe in patients with hypertension or hyperthyroidism, and patients with coronary artery disease could experience angina.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of advising patients with diabetes mellitus that epinephrine may increase blood glucose and advising patients with Parkinson's disease that the drug may cause a temporary worsening of symptoms.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;195&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For <i>self-administration</i> in anaphylaxis, instruct patients on proper techniques for storage, expiration dating (replacing before expiration), use, and disposal of prefilled auto-injectors (e.g., EpiPen<sup></sup>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;219&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;220&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;221&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;222&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of advising patients to go to the nearest emergency room after <i>self-administration</i> for anaphylaxis since further medical attention may be needed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Instruct patient to inform clinician that epinephrine was self-administered (show injection site) and to bring used auto-injector for proper disposal.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Give patients a copy of the manufacturer’s patient instructions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of not injecting the dose via the auto-injector into the thumb, finger, or hand since loss of blood flow may occur in these areas.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of seeking immediate medical attention if this occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For anaphylaxis, importance of remaining vigilant for possible recurrence despite an asymptomatic period;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;161&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;175&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; length of observation time not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;175&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Symptoms may recur within 1–36 hours after initial reaction.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;175&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Some experts suggest that patients with moderate to severe anaphylaxis should be observed for a minimum of 4–8 hours after treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant diseases.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>Effective May 1, 2016, a new USP labeling standard for Epinephrine Injection, USP has been implemented.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;227&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Concentrations of single-entity preparations of epinephrine injection will be expressed only in terms of strength per mL; use of ratios (e.g., 1:1000 or 1:10,000) to express concentrations is no longer acceptable.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;226&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;227&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Epinephrine injection 1:1000 is equivalent to 1 mg/mL and epinephrine injection 1:10,000 is equivalent to 0.1 mg/mL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;226&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;227&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>Injection</p><p>0.1 mg/mL*</p><p>EPINEPHrine Injection (available in prefilled syringes)</p><p>0.5 mg/mL</p><p>EpiPen<sup></sup> Jr. Auto-Injector (delivers a single 0.15-mg [0.3 mL] dose)</p><p>Meridian</p><p>1 mg/mL*</p><p>Adrenaclick<sup></sup> Auto-Injector (available in dose of 0.15 mg [0.15 mL] or 0.3 mg [0.3 mL])</p><p>Amedra</p><p>Adrenalin<sup></sup></p><p>Par</p><p>Auvi-Q<sup></sup> Auto-Injector (available in dose of 0.15 mg [0.15 mL] or 0.3 mg [0.3 mL])</p><p>Sanofi-Aventis</p><p>EPINEPHrine Injection</p><p>EpiPen<sup></sup> Auto-Injector (delivers a single 0.3-mg [0.3 mL] dose)</p><p>Meridian</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions August 7, 2017. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><p>† Use is not currently included in the labeling approved by the US Food and Drug Administration.</p><h2>References</h2><p>Only references cited for selected revisions after 1984 are available electronically.</p><p>43. Speer F, Tapay NJ. Syncope in children following epinephrine. <i>Ann Allergy</i>. 1970; 28:50-4. http://www.ncbi.nlm.nih.gov/pubmed/5526412?dopt=AbstractPlus</p><p>100. Barach EM, Nowak RM, Lee TG et al. Epinephrine for treatment of anaphylactic shock. <i>JAMA</i>. 1984; 251:2118-22. http://www.ncbi.nlm.nih.gov/pubmed/6708262?dopt=AbstractPlus</p><p>101. Committee on Infectious Diseases, American Academy of Pediatrics. Red book: 2015 report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</p><p>102. Food and Drug Administration. Sulfiting agents; labeling in drugs for human use; warning statement. [21 CFR Part 201] <i>Fed Regist</i>. 1986; 51:43900-5.</p><p>103. Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiac care. <i>JAMA</i>. 1992; 268:2171-2302. http://www.ncbi.nlm.nih.gov/pubmed/1404767?dopt=AbstractPlus</p><p>104. Paradis NA, Koscove EM. Epinephrine in cardiac arrest: a critical review. <i>Ann Emerg Med</i>. 1990; 19:1288-1301. http://www.ncbi.nlm.nih.gov/pubmed/2240726?dopt=AbstractPlus</p><p>105. Lindner KH, Ahnefeld FW, Bowdler IM. Comparison of different doses of epinephrine on myocardial perfusion and resuscitation success during cardiopulmonary resuscitation in a pig model. <i>Am J Emerg Med</i>. 1991; 9:27-31. http://www.ncbi.nlm.nih.gov/pubmed/1898700?dopt=AbstractPlus</p><p>106. Brown CG, Taylor RB, Werman HA et al. Effect of standard doses of epinephrine on myocardial oxygen delivery and utilization during cardiopulmonary resuscitation. <i>Crit Care Med</i>. 1988; 16:536-9. http://www.ncbi.nlm.nih.gov/pubmed/3359792?dopt=AbstractPlus</p><p>107. Brown CG, Werman HA, Davis EA et al. Comparative effect of graded doses of epinephrine on regional brain blood flow during CPR in a swine model. <i>Ann Emerg Med</i>. 1986; 15:1138-44. http://www.ncbi.nlm.nih.gov/pubmed/3752642?dopt=AbstractPlus</p><p>108. Kosnik JW, Jackson RE, Keats S et al. Dose-related response of centrally administered epinephrine on the change in aortic diastolic pressure during closed-chest massage in dogs. <i>Ann Emerg Med</i>. 1985; 14:204-8. http://www.ncbi.nlm.nih.gov/pubmed/3977143?dopt=AbstractPlus</p><p>109. Lindner KH, Ahnefeld FW, Prengel AW. Comparison of standard and high-dose adrenaline in the resuscitation of asystole and electromechanical dissociation. <i>Acta Anaesthesiol Scand</i>. 1991; 35:253-6. http://www.ncbi.nlm.nih.gov/pubmed/2038933?dopt=AbstractPlus</p><p>110. Stiell IG, Hebert PC, Weitzman BN et al. A study of high-dose epinephrine in human CPR. <i>Ann Emerg Med</i>. 1992; 21:606.</p><p>111. Callaham M, Madsen CD, Barton CW et al. A randomized clinical trial of high-dose epinephrine and norepinephrine versus standard-dose epinephrine in prehospital arrest. <i>Ann Emerg Med</i>. 1992; 21:606-7.</p><p>112. Anonymous. Advances in the management of cardiac arrest: clinical conference. <i>West J Med</i>. 1986; 145:670-5. http://www.ncbi.nlm.nih.gov/pubmed/3798915?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1307112&amp;blobtype=pdf</p><p>113. Otto C, Yakaitis R. The role of epinephrine in CPR: a reappraisal. <i>Ann Emerg Med</i>. 1987; 16:743-8. http://www.ncbi.nlm.nih.gov/pubmed/3592328?dopt=AbstractPlus</p><p>114. Callaham M. Epinephrine doses in cardiac arrest: is it time to outgrow the orthodoxy of ACLS? <i>Ann Emerg Med</i>. 1989; 18:1011-2.</p><p>115. Gonzalez ER, Ornato JP. The dose of epinephrine during cardiopulmonary resuscitation in humans: what should it be? <i>DICP, Ann Pharmacotherapy</i>. 1991; 25:773-777.</p><p>116. Callaham M, Barton CW, Kayser S. Potential complications of high-dose epinephrine therapy in patients resuscitated from cardiac arrest. <i>JAMA</i>. 1991; 265:1117-1122. http://www.ncbi.nlm.nih.gov/pubmed/1995996?dopt=AbstractPlus</p><p>117. Paradis NA, Martin GB, Rosenberg J et al. The effect of standard- and high-dose epinephrine on coronary perfusion pressure during prolonged cardiopulmonary resuscitation. <i>JAMA</i>. 1991; 265:1139-1144. http://www.ncbi.nlm.nih.gov/pubmed/1996000?dopt=AbstractPlus</p><p>118. Ornato JP. High-dose epinephrine during resuscitation: a word of caution. <i>JAMA/</i>. 1991; 265:1160-1.</p><p>119. Koscove EM, Paradis NA. Successful resuscitation from cardiac arrest using high-dose epinephrine therapy: a report of two cases. <i>JAMA</i>. 1988;259:3031-4.</p><p>120. Callaham M, Madsen CD, Barton CW et al. A randomized clinical trial of high-dose epinephrine and norepinephrine vs standard-dose epinephrine in prehospital cardiac arrest. <i>JAMA</i>. 1992; 268:2667-72. http://www.ncbi.nlm.nih.gov/pubmed/1433686?dopt=AbstractPlus</p><p>121. Callaham M. High-dose epinephrine in cardiac arrest. <i>West J Med</i>. 1991; 155:289-90. http://www.ncbi.nlm.nih.gov/pubmed/1949784?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1002993&amp;blobtype=pdf</p><p>122. Brown CG, Martin DR, Pepe PE et al. A comparison of standard-dose and high-dose epinephrine in cardiac arrest outside the hospital. <i>N Engl J Med</i>. 1992; 327:1051-5. http://www.ncbi.nlm.nih.gov/pubmed/1522841?dopt=AbstractPlus</p><p>123. Stiell IG, Hebert PC, Weitzman BN et al. High-dose epinephrine in adult cardiac arrest. <i>N Engl J Med</i>. 1992; 327:1045-50. http://www.ncbi.nlm.nih.gov/pubmed/1522840?dopt=AbstractPlus</p><p>124. Mattana J, Singhal PC. High-dose epinephrine in cardiopulmonary resuscitation. <i>N Engl J Med</i>. 1993; 328:735. http://www.ncbi.nlm.nih.gov/pubmed/8433741?dopt=AbstractPlus</p><p>125. Barton C, Callaham M. High-dose epinephrine improves the return of spontaneous circulation rates in human victims of cardiac arrest. <i>Ann Emerg Med</i>. 1991; 20:722-5. http://www.ncbi.nlm.nih.gov/pubmed/2064091?dopt=AbstractPlus</p><p>126. Hebert P, Weitzman BN, Stiell IG et al. Epinephrine in cardiopulmonary resuscitation. <i>J Emerg Med</i>. 1991; 9: 487-95. http://www.ncbi.nlm.nih.gov/pubmed/1787297?dopt=AbstractPlus</p><p>127. Goetting MG, Paradis NA. High-dose epinephrine improves outcome from pediatric cardiac arrest. <i>Ann Emerg Med</i>. 1991; 20:22-6. http://www.ncbi.nlm.nih.gov/pubmed/1984722?dopt=AbstractPlus</p><p>128. Schleien CL, dean JM, oehler RC et al. Effect of epinephrine on cerebral and myocardial perfusion in an infant animal preparation of cardiopulmonary resuscitation. <i>Circulation</i>. 1986; 73:809-17. http://www.ncbi.nlm.nih.gov/pubmed/3948377?dopt=AbstractPlus</p><p>129. Meyer JM, Wenzel CL, Kradjan WA. Salmeterol: a novel, long-acting beta 2-agonist. <i>Ann Pharmacother</i>. 1993; 27:1478-87. http://www.ncbi.nlm.nih.gov/pubmed/7905757?dopt=AbstractPlus</p><p>130. Brogden RN, Faulds D. Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. <i>Drugs</i>. 1991; 42:895-912. http://www.ncbi.nlm.nih.gov/pubmed/1723379?dopt=AbstractPlus</p><p>131. Kelly HW. Issues and advances in the pharmacotherapy of asthma. <i>J Clin Pharm Ther</i>. 1992; 17:271-81. http://www.ncbi.nlm.nih.gov/pubmed/1361192?dopt=AbstractPlus</p><p>132. Lipworth BJ. Risks versus benefits of inhaled β<sub>2</sub>-agonists in the management of asthma. <i>Drug Safety</i>. 1992; 7:54-70. http://www.ncbi.nlm.nih.gov/pubmed/1346963?dopt=AbstractPlus</p><p>133. Sears MR, Taylor DR, Print CG et al. Regular inhaled beta-agonist treatment in bronchial asthma. <i>Lancet</i>. 1990; 336:1391-6. http://www.ncbi.nlm.nih.gov/pubmed/1978871?dopt=AbstractPlus</p><p>134. Anon. Warnings from the CSM. <i>Int Pharm J</i>. 1991; 5:247-8.</p><p>135. Spitzer WO, Sussa S, Ernst P et al. The use of β-agonists and the risk of death and near death from asthma. <i>N Engl J Med</i>. 1992; 326:501-6. http://www.ncbi.nlm.nih.gov/pubmed/1346340?dopt=AbstractPlus</p><p>136. Palmer JBD, Jenkins MM. β<sub>2</sub>-agonists in asthma. <i>Lancet</i>. 1991; 337:43. http://www.ncbi.nlm.nih.gov/pubmed/1670660?dopt=AbstractPlus</p><p>137. Dahl R. β<sub>2</sub>-agonists in asthma. <i>Lancet</i>. 1991; 337:43. http://www.ncbi.nlm.nih.gov/pubmed/1670660?dopt=AbstractPlus</p><p>138. Löfdahl CG, Svedmyr N. Beta agonists—friends or foes? <i>Eur Respir J</i>. 1991; 4:1161-5. Editorial.</p><p>139. Kamada AK, Spahn JD, Blake KV. Salmeterol: its place in asthma management. <i>Ann Pharmacother</i>. 1994; 28:1100-2. http://www.ncbi.nlm.nih.gov/pubmed/7803888?dopt=AbstractPlus</p><p>140. Wanner A. Is the routine use of inhaled β-adrenergic agonists appropriate in asthma treatment? Yes. <i>Am J Respir Crit Care Med</i>. 1995; 151:597-9. http://www.ncbi.nlm.nih.gov/pubmed/7881643?dopt=AbstractPlus</p><p>141. Sears MR. Is the routine use of inhaled β-adrenergic agonists appropriate in asthma treatment? No. <i>Am J Respir Crit Care Med</i>. 1995; 151:600-1. http://www.ncbi.nlm.nih.gov/pubmed/7881644?dopt=AbstractPlus</p><p>142. Lai CKW, Twentyman OP, Holgate ST. The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the asssociated change in nonspecific bronchial responsiveness. <i>Am Rev Respir Dis</i>. 1989; 140:917-23. http://www.ncbi.nlm.nih.gov/pubmed/2572192?dopt=AbstractPlus</p><p>143. Suissa S, Ernst P, Boivin JF et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. <i>Am J Respir Crit Care Med</i>. 1994; 149(3 Part 1):604-10. http://www.ncbi.nlm.nih.gov/pubmed/8118625?dopt=AbstractPlus</p><p>144. O’Connor BJ, Aikman SL, Barnes PJ. Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. <i>N Engl J Med</i>. 1992; 327:1204-8. http://www.ncbi.nlm.nih.gov/pubmed/1357551?dopt=AbstractPlus</p><p>145. Cockcroft DW, McParland CP, Britto SA et al. Regular inhaled salbutamol and airway responsiveness to allergen. <i>Lancet</i>. 1993; 342:833-7. http://www.ncbi.nlm.nih.gov/pubmed/8104272?dopt=AbstractPlus</p><p>146. Mullen ML, Mullen B, Carey M. The association between β-agonist use and death from asthma: a meta-analytic integration of case-control studies. <i>JAMA</i>. 1993; 270:1842-5. http://www.ncbi.nlm.nih.gov/pubmed/8105113?dopt=AbstractPlus</p><p>147. Reviewers’ comments (personal observations) on Salmeterol 12:12.</p><p>148. National Institutes of Health, National Heart, Lung, and Blood Institute. Global Initiative for asthma: global strategy for asthma management and prevention NHLBI/WHO Workshop Report. Bethesda, MD: National Institutes of Health. 1995 Jan:77-100. NIH/NHLBI Publication No. 95-3659.</p><p>149. Devoy MAB, Fuller RW, Palmer JBD. Are there any detrimental effects of the use of inhaled long-acting β<sub>2</sub>-agonists in the treatment of asthma? <i>Chest</i>. 1995; 107:1116-24.</p><p>150. McFadden ER Jr. Perspectives in β<sub>2</sub>-agonist therapy: vox clamantis in deserto vel lux in tenebris? <i>J Allergy Clin Immunol</i>. 1995; 95:641-51.</p><p>151. Crane J, Burgess C, Pearce N et al. Asthma deaths in New Zealand. <i>BMJ</i>. 1992; 304:1307. http://www.ncbi.nlm.nih.gov/pubmed/1606438?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1881872&amp;blobtype=pdf</p><p>152. Crane J, Pearce N, Flatt A et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. <i>Lancet</i>. 1989; 1:917-22. http://www.ncbi.nlm.nih.gov/pubmed/2565417?dopt=AbstractPlus</p><p>154. Behringer W, Kittler H, Sterz F et al. Cumulative epinephrine dose during cardiopulmonary resuscitation and neurologic outcome. <i>Ann Intern Med</i>. 1998; 129:450- 6. http://www.ncbi.nlm.nih.gov/pubmed/9735082?dopt=AbstractPlus</p><p>155. Cummins RO, Hazinski MF. The next chapter in the high-dose epinephrine story: unfavorable neurologic outcomes? <i>Ann Intern Med</i>. 1998; 129:501-2. Editorial.</p><p>156. Carpenter TC, Stenmark KR. High-dose epinephrine is not superior to standard-dose epinephrine in pediatric in-hospital cardiopulmonary arrest. <i>Pediatrics</i>. 1997; 99403-8.</p><p>157. Pearlman DS, Chervinsky P, LaForce C et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. <i>N Engl J Med</i>. 1992; 327:1420-5. http://www.ncbi.nlm.nih.gov/pubmed/1357554?dopt=AbstractPlus</p><p>158. D’Alonzo GE, Nathan RA, Henochowicz S et al. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. <i>JAMA</i>. 1994; 271:1412-6. http://www.ncbi.nlm.nih.gov/pubmed/7909853?dopt=AbstractPlus</p><p>159. Drazen JM, Israel E, Boushey HA et al. Comparison of regularly scheduled with as- needed use of albuterol in mild asthma. <i>N Engl J Med</i>. 1996; 335:841-7. http://www.ncbi.nlm.nih.gov/pubmed/8778601?dopt=AbstractPlus</p><p>160. National Asthma Education and Prevention Program. Expert panel report III: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health National Heart Lung, and Blood Institute. (NIH publication No. 97-4051) 2007 Jul. Available from the National Heart, Lung, and Blood Institute website. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</p><p>161. The American Heart Association in Collaboration with the International Liaison Committee on Resuscitation. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2000; 102(Suppl I)I-129-30,I-142-55,I-238,I-242,I-305-7,I-352.</p><p>162. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma. Update on selected topics 2002. Bethesda, MD: National Institutes of Health National Heart Lung, and Blood Institute. (NIH publication No. 02-5074) 2003 Jun.</p><p>163. Meridian Medical Technologies. EpiPen<sup></sup> and EpiPen<sup></sup> Jr (epinephrine) auto-injector prescribing information. Columbia, MD; 2014 Apr.</p><p>164. Meridian Medical Technologies. EpiPen<sup></sup> and EpiPen<sup></sup> Jr (epinephrine) auto-injector patient information and instructions for use. Columbia, MD; 2014 Apr.</p><p>165. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins. Management of preterm labor. Washington, DC; American College of Obstetricians and Gynecologists: 2003 May. Practice Bulletin No. 43.</p><p>166. Armstrong Pharmaceuticals, Inc. Primatene<sup></sup> Mist (epinephrine) product information. West Roxbury, MA; 2015 Apr.</p><p>167. The United States pharmacopeia, 27th rev, and The national formulary, 22nd ed. Rockville, MD: The United States Pharmacopeial Convention, Inc; 2004:710-1.</p><p>169. Monarch. Adrenalin<sup></sup> chloride solution (epinephrine injection, USP) 1:1000 prescribing information. Bristol, TN: undated.</p><p>171. Epinephrine. In: Briggs GG, Freeman RK, Yaffe SJ. Drug in pregnancy and lactation: a reference guide to fetal and neonatal risk. 6th ed. Philadelphia: Lippincott Williams &amp; Wilkins; 2002:483-4.</p><p>172. Hospira. Epinephrine injection 1 mg/mL prescribing information. Lake Forest, IL: 2015 Nov.</p><p>173. American College of Obstetricians and Gynecologists (ACOG) Committee on Technical Bulletins. Preterm labor. Technical Bulletin No. 206. Washington, DC: American College of Obstetricians and Gynecologists; 1995 Jun.</p><p>174. National Institutes of Health, National Heart, Lung, and Blood Institute. Global initiative for asthma: global strategy for asthma management and prevention NHLBI/WHO Workshop Report. Bethesda, MD: National Institutes of Health. 2003 Nov 21. NIH/NHLBI Publication No. 02-3659. Available at: http://www.ginasthma.com. Accessed Sep 22, 2004.</p><p>175. The American Heart Association. Guidelines 2005 for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2005; 112(Suppl I): IV1-211.</p><p>176. Eigel B. (American Heart Association, Dallas, TX): Personal communication; 2006 Apr 27.</p><p>177. Spöhr F, Wenzel V, Böttiger BW. Drug treatment and thrombolytics during cardiopulmonary resuscitation. <i>Curr Opin Anaesthesiol</i>. 2006; 19:157-65. http://www.ncbi.nlm.nih.gov/pubmed/16552222?dopt=AbstractPlus</p><p>178. Vandycke C, Martens P. High dose versus standard dose epinephrine in cardiac arrest – a meta-analysis. <i>Resuscitation</i>. 2000; 45:161-6. http://www.ncbi.nlm.nih.gov/pubmed/10959014?dopt=AbstractPlus</p><p>179. Zhong JQ, Dorian P. Epinephrine and vasopressin during cardiopulmonary resuscitation. <i>Resuscitation</i>. 2005; 66:263-9. http://www.ncbi.nlm.nih.gov/pubmed/16039036?dopt=AbstractPlus</p><p>180. Paradis NA, Wenzel V, Southall J. Pressor drugs in the treatment of cardiac arrest. <i>Cardiol Clin</i>. 2002; 20:61-78. http://www.ncbi.nlm.nih.gov/pubmed/11845545?dopt=AbstractPlus</p><p>181. Perondi MBM, Reis AG, Paiva EF et al. A comparison of high-dose and standard-dose epinephrine in children with cardiac arrest. <i>New Engl J Med</i>. 2004; 350:1722-30. http://www.ncbi.nlm.nih.gov/pubmed/15102998?dopt=AbstractPlus</p><p>182. Epstein AE, DiMarco JP, Ellenbogen KA et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2013; 61:e6-75.</p><p>184. Jacobs IG, Finn JC, Jelinek GA et al. Effect of adrenaline on survival in out-of-hospital cardiac arrest: A randomised double-blind placebo-controlled trial. <i>Resuscitation</i>. 2011; 82:1138-43. http://www.ncbi.nlm.nih.gov/pubmed/21745533?dopt=AbstractPlus</p><p>185. Olasveengen TM, Sunde K, Brunborg C et al. Intravenous drug administration during out-of-hospital cardiac arrest: a randomized trial. <i>JAMA</i>. 2009; 302:2222-9. http://www.ncbi.nlm.nih.gov/pubmed/19934423?dopt=AbstractPlus</p><p>190. Nephron Pharmaceuticals Corporation. S2 (racepinephrine inhalation solution, USP 2.25%) product information. Orlando, FL; 2015 Feb.</p><p>191. von Mutius E, Drazen JM. A patient with asthma seeks medical advice in 1828, 1928, and 2012. <i>N Engl J Med</i>. 2012; 366:827-34. http://www.ncbi.nlm.nih.gov/pubmed/22375974?dopt=AbstractPlus</p><p>192. Food and Drug Administration, HHS. Labeling for bronchodilators to treat asthma; cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. Final rule. <i>Fed Regist</i>. 2011; 76:44475-89. http://www.ncbi.nlm.nih.gov/pubmed/21796845?dopt=AbstractPlus</p><p>193. Hospira. Epineprhine injection 0.1 mg/mL prescribing information. Lake Forest, IL; 2016 Mar.</p><p>194. Arthur G. Epinephrine: a short history. <i>Lancet Respir Med</i>. 2015; 3:350-1. http://www.ncbi.nlm.nih.gov/pubmed/25969360?dopt=AbstractPlus</p><p>195. Belcher Pharmaceuticals. Epinephrine injection USP 1 mg/mL prescribing information. Largo, FL. 2016 Feb.</p><p>196. Vanden Hoek TL, Morrison LJ, Shuster M et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010; 122(18 Suppl 3):S829-61.</p><p>197. Simons FE, Ardusso LR, Bilò MB et al. World allergy organization guidelines for the assessment and management of anaphylaxis. <i>World Allergy Organ J</i>. 2011; 4:13-37. http://www.ncbi.nlm.nih.gov/pubmed/23268454?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=3500036&amp;blobtype=pdf</p><p>198. Campbell RL, Bellolio MF, Knutson BD et al. Epinephrine in anaphylaxis: higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine. <i>J Allergy Clin Immunol Pract</i>. 2015 Jan-Feb; 3:76-80.</p><p>199. Lieberman P, Simons FE. Anaphylaxis and cardiovascular disease: therapeutic dilemmas. <i>Clin Exp Allergy</i>. 2015; 45:1288-95. http://www.ncbi.nlm.nih.gov/pubmed/25711241?dopt=AbstractPlus</p><p>200. Kemp SF, Lockey RF, Simons FE et al. Epinephrine: the drug of choice for anaphylaxis-a statement of the world allergy organization. <i>World Allergy Organ J</i>. 2008; 1(7 Suppl):S18-26. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=3666145&amp;blobtype=pdf</p><p>201. Wood JP, Traub SJ, Lipinski C. Safety of epinephrine for anaphylaxis in the emergency setting. <i>World J Emerg Med</i>. 2013; 4:245-51. http://www.ncbi.nlm.nih.gov/pubmed/25215127?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=4129903&amp;blobtype=pdf</p><p>202. Simons FE. Nonprescription availability of theophylline, epinephrine and ephedrine for asthma. <i>CMAJ</i>. 1987; 137:789. http://www.ncbi.nlm.nih.gov/pubmed/3442767?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1267346&amp;blobtype=pdf</p><p>203. Bel EH. Clinical Practice. Mild asthma. <i>N Engl J Med</i>. 2013; 369:549-57. http://www.ncbi.nlm.nih.gov/pubmed/23924005?dopt=AbstractPlus</p><p>204. Rhodes A, Evans LE, Alhazzani W et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. <i>Intensive Care Med</i>. 2017; 43:304-377. http://www.ncbi.nlm.nih.gov/pubmed/28101605?dopt=AbstractPlus</p><p>205. Cawcutt KA, Peters SG. Severe sepsis and septic shock: clinical overview and update on management. <i>Mayo Clin Proc</i>. 2014; 89:1572-8. http://www.ncbi.nlm.nih.gov/pubmed/25444488?dopt=AbstractPlus</p><p>206. Vincent JL, De Backer D. Circulatory shock. <i>N Engl J Med</i>. 2013; 369:1726-34. http://www.ncbi.nlm.nih.gov/pubmed/24171518?dopt=AbstractPlus</p><p>207. Myburgh JA, Higgins A, Jovanovska A et al. A comparison of epinephrine and norepinephrine in critically ill patients. <i>Intensive Care Med</i>. 2008; 34:2226-34. http://www.ncbi.nlm.nih.gov/pubmed/18654759?dopt=AbstractPlus</p><p>208. Hollenberg SM. Vasoactive drugs in circulatory shock. <i>Am J Respir Crit Care Med</i>. 2011; 183:847-55. http://www.ncbi.nlm.nih.gov/pubmed/21097695?dopt=AbstractPlus</p><p>209. Annane D, Vignon P, Renault A et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. <i>Lancet</i>. 2007; 370:676-84. http://www.ncbi.nlm.nih.gov/pubmed/17720019?dopt=AbstractPlus</p><p>210. Gamper G, Havel C, Arrich J et al. Vasopressors for hypotensive shock. <i>Cochrane Database Syst Rev</i>. 2016; 2:CD003709.</p><p>211. Tschudy MM, Arcara KM eds. The Harriet Lane handbook: a manual for pediatric house officers. 19th ed. Philadelphia, PA: Elsevier Mosby; 2012:782-83.</p><p>212. Amphastar Pharmaceuticals. Epinephrine injection prescribing information. So. El Monte, CA; 2008 Nov.</p><p>213. Kattwinkel J, Perlman JM, Aziz K et al. Part 15: neonatal resuscitation: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010; 122(18 Suppl 3):S909-19. http://www.ncbi.nlm.nih.gov/pubmed/20956231?dopt=AbstractPlus</p><p>214. Wyckoff MH, Aziz K, Escobedo MB et al. Part 13: Neonatal Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2015; 132(18 Suppl 2):S543-60. http://www.ncbi.nlm.nih.gov/pubmed/26473001?dopt=AbstractPlus</p><p>215. Brown RS, Rhodus NL. Epinephrine and local anesthesia revisited. <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</i>. 2005; 100:401-8. http://www.ncbi.nlm.nih.gov/pubmed/16182160?dopt=AbstractPlus</p><p>216. Council on Clinical Affairs, American Academy of Pediatric Dentistry. Guideline on Use of Local Anesthesia for Pediatric Dental Patients. <i>Pediatr Dent</i>. 2015 Sep-Oct; 37:71-7.</p><p>217. Markenson D, Ferguson JD, Chameides L et al. Part 17: first aid: 2010 American Heart Association and American Red Cross Guidelines for First Aid. <i>Circulation</i>. 2010; 122(18 Suppl 3):S934-46.</p><p>218. Hegenbarth MA, American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008; 121:433-43. http://www.ncbi.nlm.nih.gov/pubmed/18245435?dopt=AbstractPlus</p><p>219. Sanofi-Aventis. Auvi-Q<sup></sup> (epinephrine injection 0.3 mg, 0.15 mg auto-injector) prescribing information. Bridgewater, NJ; 2014 Feb.</p><p>220. Sanofi-Aventis. Auvi-Q<sup></sup> (epinephrine injection 0.3 mg, 0.15 mg auto-injector) patient information. Bridgewater, NJ; 2014 Feb.</p><p>221. Amedra Pharmaceuticals. Adrenaclick<sup></sup> (epinephrine injection 0.3 mg, 0.15 mg auto-injector) prescribing information. Horsham, PA; 2014 Oct.</p><p>222. Amedra Pharmaceuticals. Adrenaclick<sup></sup> (epinephrine injection 0.3 mg, 0.15 mg auto-injector) patient information. Horsham, PA; 2013 Apr.</p><p>223. Food and Drug Administration. FDA briefing document from the nonprescription drug advisory committee. February 26, 2014. From FDA website. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/nonprescriptiondrugsadvisorycommittee/ucm385214.pdf</p><p>224. Ralston DH, Shnider SM. The fetal and neonatal effects of regional anesthesia in obstetrics. <i>Anesthesiology</i>. 1978; 48:34-64. http://www.ncbi.nlm.nih.gov/pubmed/339784?dopt=AbstractPlus</p><p>225. Abboud TK, David S, Nagappala S et al. Maternal, fetal, and neonatal effects of lidocaine with and without epinephrine for epidural anesthesia in obstetrics. <i>Anesth Analg</i>. 1984; 63:973-9. http://www.ncbi.nlm.nih.gov/pubmed/6496982?dopt=AbstractPlus</p><p>226. Institute for Safe Medication Practices. Acute Care Medication Safety Alert Newsletter: Farewell to ratio expressions on single entity drug labels. Horsham, PA; 2015 Dec. From ISMP website. https://www.ismp.org/Newsletters/acutecare/issue.aspx?id=1111</p><p>227. United States Pharmacopeia and National Formulary (USP 39 NF 34). Rockville, MD: United States Pharmacopeia Convention; 2016:99.</p><p>228. Lieberman P, Nicklas RA, Randolph C et al. Anaphylaxis--a practice parameter update 2015. <i>Ann Allergy Asthma Immunol</i>. 2015; 115:341-84. http://www.ncbi.nlm.nih.gov/pubmed/26505932?dopt=AbstractPlus</p><p>229. Park WG, Yeh RW, Triadafilopoulos G. Injection therapies for nonvariceal bleeding disorders of the GI tract. <i>Gastrointest Endosc</i>. 2007; 66:343-54. http://www.ncbi.nlm.nih.gov/pubmed/17643711?dopt=AbstractPlus</p><p>230. Gralnek IM, Dumonceau JM, Kuipers EJ et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. <i>Endoscopy</i>. 2015; 47:a1-46.</p><p>231. Hwang JH, Fisher DA, Ben-Menachem T et al. The role of endoscopy in the management of acute non-variceal upper GI bleeding. <i>Gastrointest Endosc</i>. 2012; 75:1132-8. http://www.ncbi.nlm.nih.gov/pubmed/22624808?dopt=AbstractPlus</p><p>232. Barkun AN, Bardou M, Kuipers EJ et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. <i>Ann Intern Med</i>. 2010; 152:101-13. http://www.ncbi.nlm.nih.gov/pubmed/20083829?dopt=AbstractPlus</p><p>233. National Institute for Health and Clinical Excellence. Acute upper gastrointestinal bleeding overview. Manchester, England. 2016 Feb. From NICE website. [Web] http://pathways.nice.org.uk/pathways/acute-upper-gastrointestinal-bleeding</p><p>234. Laine L, Jensen DM. Management of patients with ulcer bleeding. <i>Am J Gastroenterol</i>. 2012; 107:345-60; quiz 361. http://www.ncbi.nlm.nih.gov/pubmed/22310222?dopt=AbstractPlus</p><p>235. Herget-Rosenthal S, Saner F, Chawla LS. Approach to hemodynamic shock and vasopressors. <i>Clin J Am Soc Nephrol</i>. 2008; 3:546-53. http://www.ncbi.nlm.nih.gov/pubmed/18256381?dopt=AbstractPlus</p><p>236. Mondal P, Kandala B, Ahrens R et al. Nonprescription racemic epinephrine for asthma. <i>J Allergy Clin Immunol Pract</i>. 2014 Sep-Oct; 2:575-8.</p><p>237. Brierley J, Carcillo JA, Choong K et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. <i>Crit Care Med</i>. 2009; 37:666-88. http://www.ncbi.nlm.nih.gov/pubmed/19325359?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=4447433&amp;blobtype=pdf</p><p>238. BPI Labs. Epinephrine injection (1 mg/mL) prescribing information. Freehold, NJ; 2014 July.</p><p>400. Link MS, Berkow LC, Kudenchuk PJ et al. Part 7: Adult Advanced Cardiovascular Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2015; 132(18 Suppl 2):S444-64. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=4771073&amp;blobtype=pdf</p><p>401. Neumar RW, Otto CW, Link MS et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010; 122(18 Suppl 3):S729-67.</p><p>402. de Caen AR, Berg MD, Chameides L et al. Part 12: Pediatric Advanced Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2015; 132(18 Suppl 2):S526-42. http://www.ncbi.nlm.nih.gov/pubmed/26473000?dopt=AbstractPlus</p><p>403. Kleinman ME, Chameides L, Schexnayder SM et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010; 122(18 Suppl 3):S876-908. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=3717258&amp;blobtype=pdf</p><p>404. Peberdy MA, Callaway CW, Neumar RW et al. Part 9: post-cardiac arrest care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010; 122(18 Suppl 3):S768-86.</p><p>a. AHFS Drug Information 2017. McEvoy, GK, ed. Epinephrine/Racepinephrine. Bethesda, MD: American Society of Health-System Pharmacists; 2017.</p><p>HID. McEvoy GK, ed. Handbook on injectable drugs. 18th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2015:451-5.</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Norepinephrine vs epinephrine: what's the difference?</li>
</ul><h2>More about epinephrine</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>36 Reviews</li>
<li>Drug class: adrenergic bronchodilators</li>
<li>FDA Alerts (2)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li data-more-config-id="list-data-resources-consumer">... +3 more</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li>EPINEPHrine (Systemic) &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Professional Patient Advice)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
<li>Epinephrine Concentrate Injection &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
<li>Epinephrine Injection &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Allergic Reactions</li>
<li>AV Heart Block</li>
<li>Asthma, acute</li>
<li>Adams-Stokes Syndrome</li>
<li data-more-config-id="list-data-resources-conditions">... +8 more</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>